Strong Development Pipeline

A diverse pipeline designed to address significant unmet medical needs

We are focused on developing a new generation of targeted, empowered antibody-based therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.

Brentuximab Vedotin

Hodgkin Lymphoma (HL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

ECHELON-1: Frontline HL

Top-line data reported

CHECKMATE 812: Relapsed HL (+ nivolumab, an immunotherapy)

Enrolling

Frontline HL in patients ≥ 60 (± chemotherapy or nivolumab, an immunotherapy)

Enrolling

Second-line HL (+ nivolumab, an immunotherapy)

Enrolling

Non-Hodgkin Lymphoma (NHL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

ALCANZA: Relapsed CD30-expressing cutaneous T-cell lymphoma

sBLA submitted to FDA

ECHELON-2: Frontline CD30-expressing mature T-cell lymphoma

Enrollment complete

Relapsed NHL (+ nivolumab, an immunotherapy)

Enrolling

Other Programs

Solid Tumors

Target: Nectin-4

Technology Platform: ADC using MMAE

Collaborator:

Metastatic urothelial cancer

Planned

Tisotumab vedotin

Target: Tissue factor

Technology Platform: ADC using MMAE

Recurrent cervical cancer

Enrolling

Target: LIV-1

Technology Platform: ADC using MMAE

Metastatic breast cancer

Enrolling

Target: SLITRK6

Technology Platform: ADC using MMAE

Collaborator:

Metastatic urothelial cancer

Enrolling

NHL

Target: CD19

Technology Platform: ADC using MMAF

Frontline and relapsed diffuse large B-cell lymphoma

Enrolling

Target: CD19

Technology Platform: ADC using PBD

Relapsed/refractory aggressive B-cell NHL

Enrolling

Leukemia & Myelodysplastic Syndrome (MDS)

Target: CD33

Technology Platform: ADC using PBD

Frontline MDS

Suspended

Frontline younger AML

Suspended

Target: CD123

Technology Platform: ADC using PBD

Relapsed/refractory AML

Enrolling

Multiple Myeloma

Target: CD352

Technology Platform: ADC using PBD

Relapsed/refractory multiple myeloma

Enrolling

SGN-CD48A

Target: CD48

Technology Platform: ADC using MMAE

Relapsed/refractory multiple myeloma

Planned

Immuno-Oncology

Technology Platform: sugar engineered antibody targeting CD40, an immune-activating receptor capable of driving an antitumor response

Advanced solid and hematologic malignancies

Enrolling

Technology Platform: An oral immuno-oncology agent that inhibits fucosylation

Advanced solid tumors

Enrolling